Loading...

James S. Hu, MD

Title(s)Clinical Associate Professor of Medicine (Clinician Educator)
AddressNOR 3440
Health Sciences Campus
Los Angeles CA 90089-9173
Phone+1 323 865 0813
vCardDownload vCard

    Collapse Biography 
    Collapse Awards and Honors
    American College of Physicians2006Fellow
    Keck School of Medicine2011Oncology Fellowship Teacher of the Year
    2013Meritorious Service Medal

    Collapse Overview 
    Collapse Overview
    James Hu, MD, FACP, is the medical director of the Sarcoma Program of USC, and is considered one of the nation’s experts in the disease. Dr. Hu has more than 20 years of clinical experience in medical oncology and brings this acumen to the bedside. Understanding the rarity of sarcoma cancers, Dr. Hu has the breadth of clinical experience as well as the academic discipline to provide each patient with an individualized treatment program. He has collaborated with other national experts to bring clinical trials to USC. He is a member of the Connective Tissue Oncology Society, and has linked the Sarcoma Program of USC with the international collaborative group: Sarcoma Alliance for Research through Collaboration (SARC), to further direct research into sarcoma.

    Dr Hu has authored several review articles on sarcoma, in both national and international peer reviewed journals. As a former military commander of a combat support hospital, Dr. Hu has years of experience in the issues surrounding young adult disease and along with Dr. Siegel, is the co-director of the Adolescent and Young Adult program of USC and Children’s Hospital Los Angeles. This program offers specialized services tailored to adolescent and young adult patients who comprise a significant portion of patients diagnosed with sarcomas. Dr Hu and his medical oncology team pride themselves on patient accessibility and are committed to providing comprehensive oncology care to the patient with sarcoma.

    Dr. Hu is a local Angeleno, having grown up in the neighborhood surrounding LAC+USC Medical Center. Dr Hu is proud to be a part of USC and grateful for an opportunity to give back to his community.

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Predictors of readmission after craniotomy for meningioma resection: a nationwide readmission database analysis. Acta Neurochir (Wien). 2020 Aug 11. Lin M, Min E, Orloff EA, Ding L, Youssef KSR, Hu JS, Giannotta SL, Mack WJ, Attenello FJ. PMID: 32779026.
      View in: PubMed   Mentions:    Fields:    
    2. Staging systems and nomograms in soft tissue sarcoma: outcome prediction by categorization or personalization? Chin Clin Oncol. 2019 Oct; 8(S1):S12. Tseng WW, Pasquali S, Hu JS, Menendez LR, Gronchi A. PMID: 30943728.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    3. Talimogene laherparepvec in combination with pembrolizumab leads to a complete response in a patient with refractory Merkel cell carcinoma. JAAD Case Rep. 2018 Nov; 4(10):1004-1006. Lara KM, In GK, Matcuk GR, Mehta A, Hu JS. PMID: 30450405.
      View in: PubMed   Mentions:
    4. Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer. Cancer. 2017 Dec 01; 123(23):4566-4573. Dorff TB, Longmate JA, Pal SK, Stadler WM, Fishman MN, Vaishampayan UN, Rao A, Pinksi JK, Hu JS, Quinn DI, Lara PN. PMID: 28832978.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    5. Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations. Ther Adv Med Oncol. 2017 Aug; 9(8):533-550. In GK, Hu JS, Tseng WW. PMID: 28794805.
      View in: PubMed   Mentions:
    6. Contemporary Management of Retroperitoneal Soft Tissue Sarcomas. Curr Oncol Rep. 2015 Aug; 17(8):39. Olimpiadi Y, Song S, Hu JS, Matcuk GR, Chopra S, Eisenberg BL, Sener SF, Tseng WW. PMID: 26092408.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    7. Contrast-Enhanced Sonography for Monitoring Neoadjuvant Chemotherapy in Soft Tissue Sarcomas. J Ultrasound Med. 2015 Aug; 34(8):1489-99. Gulati M, Hu JS, Desai B, Hwang DH, Grant EG, Duddalwar VA. PMID: 26206837.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    8. Salvage chemotherapy for refractory germ cell tumors. Oncology (Williston Park). 2014 Jun; 28(6):498-500. Dorff TB, Hu JS, Quinn DI. PMID: 25134324.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    James's Networks
    Concepts (37)
    Derived automatically from this person's publications.
    _
    Co-Authors (15)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _